Harbor Capital Advisors Inc. Has $3.16 Million Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)

Harbor Capital Advisors Inc. lessened its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 23.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 118,500 shares of the company’s stock after selling 35,407 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Castle Biosciences were worth $3,158,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CSTL. Principal Financial Group Inc. raised its position in shares of Castle Biosciences by 2.7% during the third quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company’s stock worth $43,879,000 after purchasing an additional 40,377 shares during the period. Bellevue Group AG increased its stake in Castle Biosciences by 3.7% during the 3rd quarter. Bellevue Group AG now owns 1,262,030 shares of the company’s stock worth $35,993,000 after purchasing an additional 44,929 shares in the last quarter. Portolan Capital Management LLC raised its holdings in Castle Biosciences by 3.7% during the 3rd quarter. Portolan Capital Management LLC now owns 1,255,628 shares of the company’s stock worth $35,811,000 after buying an additional 44,676 shares during the period. Dimensional Fund Advisors LP raised its holdings in Castle Biosciences by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 809,934 shares of the company’s stock worth $17,631,000 after buying an additional 60,675 shares during the period. Finally, State Street Corp lifted its stake in Castle Biosciences by 9.8% in the third quarter. State Street Corp now owns 680,001 shares of the company’s stock valued at $19,394,000 after buying an additional 60,924 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

CSTL has been the subject of several research reports. Stephens reissued an “overweight” rating and set a $41.00 price objective on shares of Castle Biosciences in a research report on Thursday, January 2nd. BTIG Research lifted their price target on Castle Biosciences from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Robert W. Baird upped their price objective on Castle Biosciences from $37.00 to $39.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Lake Street Capital lifted their target price on Castle Biosciences from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Finally, Scotiabank boosted their target price on Castle Biosciences from $37.00 to $44.00 and gave the company a “sector outperform” rating in a research note on Wednesday, November 6th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $40.29.

Castle Biosciences Stock Performance

CSTL opened at $30.25 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. The business’s 50-day simple moving average is $29.81 and its 200 day simple moving average is $27.87. The firm has a market capitalization of $847.21 million, a PE ratio of 151.26 and a beta of 0.92. Castle Biosciences, Inc. has a 52-week low of $16.97 and a 52-week high of $35.84.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings data on Monday, November 4th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.14. The company had revenue of $85.78 million during the quarter, compared to the consensus estimate of $78.55 million. Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%. During the same quarter in the prior year, the firm posted ($0.26) EPS. As a group, sell-side analysts expect that Castle Biosciences, Inc. will post 0.34 earnings per share for the current fiscal year.

Insider Transactions at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 1,972 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $34.15, for a total value of $67,343.80. Following the transaction, the insider now directly owns 87,720 shares in the company, valued at $2,995,638. The trade was a 2.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tobin W. Juvenal sold 3,507 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $35.56, for a total transaction of $124,708.92. Following the sale, the insider now owns 54,178 shares of the company’s stock, valued at approximately $1,926,569.68. This represents a 6.08 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 36,292 shares of company stock worth $1,099,755 in the last ninety days. Insiders own 7.20% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.